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ZUSAMMENFASSUNG 
 Antivaskuläre Therapie von malignen Tumoren mittels 
Fusionspolypeptiden bestehend aus Gewebefaktor und RGD Peptiden 
Federico Herrera Alemán 
 
Die selektive Aktivierung der Blutgerinnung in Tumorblutgefäßen ist ein 
vielversprechender antivaskulärer Therapieansatz zur Behandlung bösartiger Tumoren. 
Aus der Thrombusbildung resultiert eine konsekutive Tumornekrose. Für eine solche 
Strategie wurden Fusionsproteine generiert, die aus löslichem Gewebefaktor (truncated 
tissue factor, kurz tTF, welcher die Blutgerinnung aktiviert) und Oligopeptiden 
bestehen, die die selektive Bindung an Rezeptoren der Tumor-Endothelzelle vermitteln. 
Das tTF-Fusionspolypeptid tTF-GRGDSP (kurz: tTF-RGD) wurde stabil exprimiert, 
gereinigt, biochemisch umfassend charakterisiert und anschließend an Transplantaten 
menschlicher Tumoren (humanes Lungenkarzinom, malignes Melanon) im Mausmodell 
evaluiert. Die Tumoren der mit tTF-RGD Fusionsprotein behandelten Mäuse wurden im 
Vergleich zu tTF oder NaCl in ihrem Wachstum signifikant gehemmt. 
Histologische untersuchungen belegen den Wirkungsmechanismus der Induktion einer 
selektiven Tumorgefäßthrombose mit konsekutiver Tumornekrose. 
Eine relevante Organtoxizität wurde auch bei Dosen der tTF-Fusionsproteine, die das 
mehrfach der therapeutisch effektiven Dosis überschrieten, weder makroskopisch noch 
mikroskopisch beobachtet. 
 
Genehmigung durch die Bezirksregierung Münster am 2000 
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Tag der mündlichen Prüfung 29.11.04 
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Introduction 
Angiogenesis, i.e., the proliferation of new blood vessels from preexisting 
ones, is a characteristic feature of aggressive solid tumors (Folkman et al, 
1989). Molecules capable of inhibiting angiogenesis or of selectively 
targeting and destroying new blood vessels, would be promising agents for 
the treatment of angiogenesis-related diseases.  
Tissue factor (TF) is a cell-surface glycoprotein and a major initiator of 
blood coagulation. At sites of injury, blood comes in contact with the 
membrane-bound  TF, which forms a complex with the serine protease 
FVIIa present in blood. 
The resulting complex activates factors IX and X, which leads to thrombin 
activation and ultimately to blood clotting. Truncated tissue factor (tTF) 
consisting of only the extra cellular soluble domain (residues 1–219), 
exhibits an ability to activate the clotting cascade in solution that is five 
orders of magnitude lower than full length tissue factor incorporated in a 
phospholipid membrane. When tTF is relocated to a phospholipid 
membrane, tTF regains full activity like native tissue factor. 
 
New approaches are targeting not the tumor cells but the endothelial cells 
on tumors. Vascular targeting requires the identification of target molecules 
that are present at sufficient density on the surface of vascular endothelium 
in solid tumors but absent from endothelial cells in normal tissues. Such 
molecules could be used to target cytotoxic agents to the vascular 
endothelium of the tumor rather than to the tumor cells themselves. 
Promising candidate molecules include bFGF (basic fibroblast growth 
factor), VEGF (vascular endothelial growth factor) and VEGF receptor 2 
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(VEGFR-2), endoglin, endosialin, a fibronectin isoform (ED-B domain), 
the integrins αVβ3, αVβ5, α1β1, α2β1, amino peptidase N, NG2 proteoglycan 
and the matrix metalloproteinases 2 and 9 (MMP 2 and 9) (Dvorak et al, 
1991 and 1995; Burrows et al, 1995; Carmemolla et al, 1989; Arap et al, 
1998; Bhagwat et al, 2001; Burg et al, 1999; Kessler et al 2002; Morrissey 
et al, 1993; Olson et al, 1997; Rettig et al, 1992; Sengeer et al, 1997; 
Pfeifer et al, 2000). 
 
A novel approach to cancer therapy based on targeting of the human 
coagulation-inducing protein tTF to tumor vasculature has recently been 
proposed ( Huang et al, 1997; Ran et al, 1998; Nilsson et al, 2001; Liu et al, 
2002; Peisheng et al, 2003). The approach is based on the concept that 
thrombosis of tumor vessels may stop the supply of nutrients and oxygen to 
tumor cells, thereby causing their death.  
 
The targeted delivery of tTF would be of significant therapeutic relevance if 
it is directed against a naturally occurring marker of tumor angiogenesis, 
and if it mediates the selective thrombosis of tumor blood vessels 
sufficiently to inhibit the tumor growth or to generate tumor infarction. 
 
In this work we show that a protein consisting of the RGD peptide fused to 
tTF mediates the selective tumor growth inhibition of two different types of 
solid human tumors; the lung cancer (CCL185) and the malignant 
melanoma (M21) in murine tumor models.  
 
 
 
 
  
10
10
Angiogenesis 
 
Angiogenesis is defined as a process of vascular neoformation out of 
existing ones, that occurs during development, menstruation and several 
pathological conditions such as rheumatoid arthritis, age-related macular 
degeneration, proliferative retinopathies, and psoriasis as well as tumor 
growth and metastasis. Compensatory angiogenesis is demonstrated in the 
formation of collateral blood vessels when there is oxygen or nutrient 
deprivation in normal tissues. Despite the fact that angiogenesis refers to 
the derivation of blood vessels of all types (micro and macro vessels), the 
term is usually restricted to the neoformation of capillary blood vessels. 
Angiogenesis requires the coordinated activation of genes that are 
responsible for proliferation, migration and differentiation of endothelial 
cells to form capillary-like structures. The activation of these genes is 
thought to occur through paracrine factors also, the genes activated by 
these factors encode autocrine/intracrine secondary regulators, proteolytic 
enzymes, and molecules that are direct downstream substrates of 
endothelial cytokine receptors (Bikfalvi, 1995). 
 
The coagulation system and angiogenesis 
 
Angiogenesis is the process of sprouting and configuring new blood vessels 
from pre-existing blood vessels, whereas the haemostatic system maintains 
the liquid flow of blood by regulating platelet adherence and fibrin 
deposition. Both systems normally appear quiescent. With vessel injury, a 
rapid sequence of reactions must occur to occlude the vessel wall defect 
and prevent hemorrhage. Activated platelets link the margins of the defect 
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and form a provisional barrier that is quickly enmeshed with polymerized 
fibrin. This clot structure initially requires immobilized vascular 
endothelial cells to anchor the clot and prevent further bleeding. Thereafter, 
endothelial cells at the clot margins become mobile, dismantling and 
invading the cross-linked fibrin structure to rebuild a new vessel wall. 
 
Although the positive and negative regulators that control the delicate 
balance of platelet reactivity and fibrin deposition have been elucidated 
over the past four decades, analogous proteins that control endothelial cell 
growth and inhibition have only been discovered within the past decade. 
Hemostasis and angiogenesis are becoming increasingly inter-related 
pathways generated by the haemostatic system, coordinating the spatial 
localization and temporal sequence of clot / endothelial cell stabilization 
followed by endothelial cell growth and repair of a damaged blood vessel. 
To date, a limited number of these proteins have been identified (Browder 
et al, 2000). 
 
Role of angiogenesis in cancer 
 
Angiogenesis performs a critical role in the development of cancer, solid 
tumors smaller than 1 to 2 cubic millimeters are nor vascularized to spread, 
they need to be supplied by blood vessels that bring oxygen and nutrients 
and remove metabolic wastes. 
New blood vessel development is an important process in tumor 
progression. It favors the transition from hyperplasia to neoplasia i.e. the 
passage from a state of cellular multiplication to a state of uncontrolled 
proliferation characteristic of tumor cells. 
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100 years ago researchers observed that angiogenesis occurs around tumors 
(Kerbel et al, 2000; Algire et al, 1945). 
In 1971 it was proposed that tumor growth beyond 1 to 2 mm in size and 
metastasis are angiogenesis dependent and hence blocking angiogenesis 
could be a strategy to arrest tumor growth (Folkman, 1971and 1990), thus 
tumor cells that undergo the phenotypic switch are able to induce changes 
in endothelial cells, leading to angiogenesis and to a growing tumor 
(Polverini, 1996).  
 
Tumor cells and infiltrating cells such as macrophages and fibroblasts 
activate the endothelial cells, thus initiating angiogenesis by expressing 
factors such as VEGF and bFGF. Once neovascularization occurs, the 
tumor experience rapid growth and an increased metastatic potential (Poon 
et al, 2001; Mattern et al, 1996; Toi et al, 1994).  
Angiogenesis involves a series of steps, including endothelial cell 
proliferation, differentiation, migration, and organization to form tubules 
(Dvorak et al, 1995), because of this stepwise process anti-angiogenic 
therapy can be developed against any of several steps in the process and 
can be used to stop or to inhibit pathologies that involves such processes 
(Lee, 2002).  
 
Recent data strongly suggest an important role of angiogenesis in 
hematological malignancies. Thus anti-angiogenic therapy could constitute 
a novel strategy not only for the treatment of solid tumors or inflammatory 
disorders but also malignancies like acute myeloid leukemia (Padró et al, 
2000; Mesters et al, 2001).  
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Regulators of tumor angiogenesis 
 
At the site of vessel injury, adhered platelets secrete both positive and 
negative regulators of angiogenesis, mainly from internal α granules. 
The positive regulators include: vascular endothelial growth factor-A 
(VEGF-A), vascular endothelial growth factor-C (VEGF-C), basic 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), 
angiopoietin-1, insulin-like growth factor-1 and –2 (IGF-1-2), epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and 
sphingosine 1 phosphate (Mohle et al, 1997; Wartiovaara et al, 1998; 
Brunner et al, 1993; Nakamura et al, 1986; Karey et al, 1989; Ben-Ezra et 
al, 1990; Hwang et al, 1992; Bar et al, 1989; Lee et al, 1999). 
 
Numerous investigators have evaluated the presence of angiogenic peptide, 
in particular bFGF and VEGF in clinical body fluids in an effort to explore 
the usefulness of these measurements as potential clinical parameters. Most 
of these studies are exploratory and suggest a correlation between 
detectable levels of these peptides and clinical outcome. 
There was a relatively good correlation between serum but not urinary 
bFGF levels and tumor stage or grade in a small number of patients with 
renal cell carcinoma (Rippmann et al, 2000). More recently, a significant 
over expression of VEGF and its cellular receptor KDR (VEGFR-2) and 
bFGF in the bone marrow of patients with acute myeloid leukemia was 
found (Padró et al, 2002; Bieker et al, 2003). 
An increased presence of matrix metalloproteinases (MMPs) may be 
related to increased invasive, metastasis, and angiogenic potential of 
tumors. 
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The hepatocyte growth factor (HGF) secretes also negative regulators that 
suppress the inducement of angiogenesis. The anti-angiogenic HGF 
fragments consisting of either the NK1 or NK2 cringle domains suppresses 
HGF induced endothelial cell migration. This anti-angiogenic fragments 
inhibit tumor growth in vivo by increasing tumor cell apoptosis without 
affecting the proliferation rate of tumor cells (Date et al, 1998). 
Thrombospondin (TSP-1) re-adjusts growth factor and integrin signaling 
pathways between endothelial cells and the fibrin clot and prevent 
endothelial cell motility induced by fibrin, also blocks the chemotactic 
response of endothelial cells to bFGF (Good et al, 1990).  
Plasminogen activator inhibitor type 1 (PAI-1), alpha 2 antiplasmin and 
alpha 2-macroglobulin suppress angiogenesis by limiting plasmin 
generation within the clot structure (Blei et al, 1993).  
 
Metastasis 
 
New blood vessel development is an important process in tumor 
progression. Neovascularization also influences the dissemination of cancer 
cells throughout the entire body eventually leading to metastasis formation. 
It has been suggested in the past that the growth of primary solid tumors is 
strictly dependent on their ability to induce angiogenesis from the 
surrounding vasculature, so that tumor progression including invasion and 
metastasis, involves the different phases pre-vascular and vascular 
(Gimbrone et al, 1972).  
It has been also observed that removal of primary tumor can be followed by 
a rapid onset of metastasis. This would suggest that a primary tumor can 
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inhibit its metastasis growth, then the switch to an angiogenic phenotype 
depends upon the net balance of angiogenic stimulators and inhibitors.  
The development of metastasis is then greatly influenced by angiogenesis 
(Bikfalvi, 1995). Also since primary tumor growth is often controlled with 
surgery and/or irradiation, anti-angiogenic agents may be most beneficial in 
the treatment of widespread metastasis disease. However, several principles 
must be understood; anti-angiogenic therapy may need to be delivered on a 
chronic basis since this type of therapy is not cytotoxic but rather only 
prevents further growth of a tumor. 
Secondly, the endpoint of anti-angiogenic therapy would not be tumor 
shrinkage, but rather tumor stabilization (Ellis et al, 1996), recognizing that 
angiogenesis is one step in the multistep process of metastasis (Fidler et al, 
1994).  
 
Some researchers selectively targeted tumor blood vessels in vivo, using 
artificial or naturally occurring markers of angiogenesis with results of 
therapeutic relevance (Huang et al, 1997; Ran et al, 1998; Nilsson et al, 
2001; Liu et al, 2002; Peisheng et al, 2003). 
Also it has been assumed that anti-angiogenic therapy of any type might 
have to be delivered for the rest of a patient’s life, or at least for many years 
(Boehm et al, 1997). 
 
Mediators of tumor angiogenesis 
 
A large number of angiogenic factors produced by tumor cells themselves 
and by accessory host cells such as macrophages, mast cells and 
lymphocytes have been identified. 
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Recent attention has been focused on members of the fibroblast growth 
factors (FGF) and vascular endothelial growth factors (VEGF) families as 
the most common tumor angiogenic factors (Fernig, 1994; Dvorak et al, 
1995; Claffey et al, 1996), (See table 1). 
 
These cytokines stimulate migration and proliferation of endothelial cells 
(ECs). The biological effect of VEGF is mediated by the binding to two 
different receptors, VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR), that are 
mainly expressed on ECs (Terman et al, 1996). 
 
Recently, neuropilin 1 has been identified as a third VEGF receptor that 
exclusively binds to the VEGF165 splice variant and modulates binding of 
VEGF to VEGFR-1 and VEGFR-2 (Soker et al, 1990). VEGF and its 
receptors are over expressed in the vast majority of human tumors. 
 
The importance of VEGF is underscored by the fact that blocking of VEGF 
function results in suppression of angiogenesis and growth of a variety of 
tumors in vivo (Kim et al, 1993; Millauer et al, 1994; Warren et al, 1995; 
Cheng et al, 1996; Millauer et al, 1996; Skobe et al, 1997).  
 
Integrins have been identified as additional key molecules of tumor 
angiogenesis. These integrins play a pivotal role in mediating cell to cell 
and cell to matrix interactions, essential components for tumor 
angiogenesis and metastasis (Brooks et al, 1994a and 1994b; Yun et al, 
1996; Senger et al, 1997; Ruegg et al, 1998). 
 
Certain integrins (e.g. αVβ3, αVβ5 and others) are specifically and 
selectively expressed on the tumor vasculature in high density, but outside 
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of the female reproductive tract these integrins are not expressed under 
physiological conditions on ECs. 
 
The process of anti-angiogenesis 
 
Based on observations that expansion of a tumor mass was limited in the 
absence of angiogenesis, considerable experimental supporting evidence 
for this concept has been assembled from inhibition of angiogenesis by: 
 
• Mechanical separation of tumor cells from their nearest vascular bed 
(Gimbrone et al, 1972) 
• Blockade of tumor-derived angiogenic factors (Kim et al, 1993)  
• Administration of angiogenesis inhibitors (Boehm et al, 1997)  
• Endogenous production of angiogenesis inhibitors from tumor cells 
(Bouck, 1990; Cao et al, 1998). 
• Demonstration of the pre angiogenic phenotype in spontaneous 
tumors (Hanahan et al, 1996).  
 
Anti-angiogenic treatment strategies 
 
The principal target for anti-angiogenic therapy is represented by 
proliferating ECs, which with the exception of the female reproductive tract 
are in a quiescent state in normal tissues. 
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Only one of 10.000 ECs (0,01%) is in cell division at a certain point 
(Engerman et al, 1967; Hobson et al, 1984). 
As a response to a certain stimulus ECs leave the quiescent state and 
proliferate as fast as haematopoietic cells from the bone marrow or 
epithelial cells from the mucosa of the gastrointestinal tract.  
Based on the current knowledge of angiogenesis, which is a complex 
process of EC proliferation, selective degradation of the basement 
membrane, extracellular matrix and subsequent EC migration (Folkman et 
al, 1992).The following anti-angiogenic strategies are currently under 
investigation: 
 
• Interfering with receptor binding or activation of a particular 
angiogenic factor. 
• Inhibiting the release of a particular angiogenic factor by tumor cells. 
• Enhancing the production or action of an angiogenic inhibitor. 
• Being similar or identical to a particular angiogenic inhibitor. 
• Interfering with signal transduction processes in an autocrine / 
intracrine activation of capillary endothelial cells. 
• Inhibiting the matrix degradation by protease matrix degrading 
enzymes (Bikfalvi, 1995; Sato et al, 1990). 
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Angiogenesis inhibitors 
 
Numerous angiogenic inhibitors have been identified (Hagedorn et al, 
2000) and many are now in clinical trials. Whereas some agents, such as 
antibodies to VEGF and VEGFR2, continue to show promise, a few drugs 
have proved disappointing (Coussens et al, 2002).  
Nevertheless, there is still intense interest in angiogenesis inhibitors as 
future clinical tools and much work is in progress (Novak, 2002). 
 
There are two classes of angiogenesis inhibitors “direct and indirect”:  
 
• Direct angiogenesis inhibitors, such as vitaxin, angiostatin and 
others, prevent vascular endothelial cells from proliferating, 
migrating or avoiding cell death in response to a spectrum of pro-
angiogenic proteins, including VEGF, bFGF, IL-8 and platelet-
derived growth factor (PDGF).  
 
• Indirect angiogenesis inhibitors generally prevent the expression of 
or block the activity of a tumor protein that activates angiogenesis 
also blocking the expression of its receptor on endothelial cells. 
 
Direct angiogenesis inhibitors are the least likely to induce acquired drug 
resistance, because they targeted genetically stable endothelial cells rather 
than unstable mutating tumor cells. (See table 1). 
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Pro-angiogenic factors Anti-angiogenic factors 
Angiogenin Angiostatin (plasminogen fragment) 
Angiopoetin-1 Endostatin (collagen XVIII fragment) 
Del-1 Cartilage-derived inhibitor (CD1) 
Fibroblast growth factor, acidic (bFGF) CD59 complement fragment 
Antiangiogenic antithrombin III Fibronectin fragment 
Fibroblast growth factor, basic (bFGF) Gro-beta 
Follistatin Heparinases 
Transforming growth factor beta (TGF- ß) 
Granulocyte colony-stimulating factor (G-
CSF) 
Heparin hexasaccharide fragment 
Hepatocyte growth factor (HGF) Human chorionic gonadotropin (hCG) 
Interleukin-8 (IL-8) Interferon inducible protein (IP-10) 
Leptin Interferon alpha, beta, gamma 
Midkine Interleukin 12 (IL-12) 
Placental growth factor (PiGF) Cringle 5 (plasminogen fragment) 
Platelet-derived endothelial cell growth 
factor (PD-ECGF) 
Tissue inhibitors of metalloproteinases (TIMPs)
Platelet-derived growth factor-BB(PDGF-
BB) 
2-Methoxyestradiol 
Pleiotrophin (PTN) Placental ribonuclease inhibitor 
Proliferin Plasminogen activator inhibitor 
Transforming growth factor-alpha (TGF-
alpha) 
Platelet factor 4 (PF4) 
Transforming growth factor beta (TGF-beta) Prolactin 16kD fragment 
Tumor necrosis factor-alpha (TNF-a) Retinoids 
Vascular endothelial growth factor (VEGF) Tetrahydrocortisol-S 
 Thrombospondin-1 (TSP-1) 
 Vasculostatin 
 Vasostatin (calreticulin fragment) 
Table 1 Pro-angiogenic and Anti-angiogenic factors. 
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In this way two approaches have been adopted: first, the use of antibodies 
to either VEGF or VEGF receptors, and second, the development of 
specific inhibitors of the VEGF receptor tyrosine kinase.  
 
Ferrara and colleagues were the first to show that antibodies to VEGF 
slowed tumor growth (Kim et al, 1993), and humanized forms are now in 
Phase III clinical trials for the treatment of solid tumors. 
Because of the difficulties and expense of using biological agents in the 
clinic, others set out to identify low-molecular-weight inhibitors of the 
tyrosine kinase activity of KDR (VEGFR2 in humans), also with promising 
results in hematological malignancies.  
 
In this way several compounds have been identified and are undergoing 
clinical evaluation (Bikfalvi et al, 2002; Mesters et al, 2000). 
 
Inhibitors of the KDR VEGF receptor tyrosine kinase 
Developer Compound Clinical stage 
Pharmacia (Sugen) SU101 No longer in 
development 
Pharmacia (Sugen) SU5416 No longer in 
development 
Pharmacia (Sugen) SU6668 Phase II 
AstraZeneca ZD4190 Phase II 
 Novartis PTK787ZK222584 Phase II 
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Gene treatment approaches in anti-angiogenesis 
 
Based on inhibition of angiogenesis by gene therapy Lin et al, used an 
adenoviral vector to deliver a recombinant Tie2 receptor (tirosine kinase 
receptor) that blocked activation of the Tie2 receptor on endothelial cells.  
 
Most important, delivery of the soluble Tie2 receptor-adenoviral construct 
at the time of surgical excision of primary tumors also inhibited subsequent 
metastasis growth, demonstrating that gene therapy directed against the 
Tie2 receptor on endothelial cells will inhibit tumor angiogenesis (Lin et al, 
1998).  
 
Goldman et al, reported the use of an ex vivo gene transfer method to 
transfect stable human tumor cells with the cDNA encoding a truncated 
form of native soluble FLT-1, a receptor for the angiogenic factor VEGF. 
Soluble FLT-1 inhibited VEGF function (Goldman et al, 1998).  
 
Moreover, researchers have to consider the local vs. systemic anti-
angiogenic gene therapy, and direct vs. indirect anti-angiogenic gene 
therapy (Folkman, 1998).  
 
Also, combinations of angiogenesis inhibitors and conventional cytotoxic 
chemotherapy cured tumors in mice when either therapy alone could not 
accomplish this (Teicher et al, 1994).  
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In the future, systemic anti-angiogenic therapy may be used:  
 
• After surgery or after radiotherapy to prevent recurrence of distant 
metastases.  
• In combination with conventional chemotherapy 
• In combination with vaccine therapy or immunetherapy  
• In combination with others types of gene therapy, for example delivery 
of tumor suppressor genes. 
 
Vascular targets 
 
Two types of vascular target agents (VTAs) are currently being developed 
for cancer treatment: 
a) The ligand-directed VTAs, which use antibodies and peptides to 
target toxins, pro-coagulants, and pro-apoptotic effectors to tumor 
endothelium. 
 
b) The small molecules that do not specifically localize to tumor 
endothelium, but which exploit pathophysiological differences 
between tumor and normal tissue endothelia to induce selective 
occlusion of tumor vessels (Ching et al, 1999), (See table 2). 
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Vascular targeting of malignant tumors has been shown to be a new 
potential approach for the treatment of cancer (Huang et al, 1997), and 
some of the advantages over conventional anti-tumor cell therapies are: 
 
1.  target antigen is directly accessible, and penetration of drugs 
through the tumor tissue, which has been defined as a major 
problem in the treatment of solid tumors is not 
necessary.(Baxter et al, 1989; Fujimori et al, 1989; Jain, 
1990). 
 
2. There is a potentiation effect because the killing of one 
endothelial cell results in the death of thousands of tumor cells 
(Denekamp, 1990), and the coagulation process is a cascade in 
which one molecule of initiating coagulation factors results in 
the generation of millions of molecules fibrin per minute. 
 
3. The target cells are unlikely to acquire genetic mutations and 
to develop a drug resistance (Boehm et al, 1997).  
 
The same targeted drug can be used for a variety of solid tumors because 
the target antigen should be present in many different tumors, also a 
surrogate marker of biological activity (i.e., blood flow) is measurable in 
the clinic and temporary effects on vascular function may be sufficient.  
 
Studies indicate that > 99 % of tumor cells in vivo can be killed during a 2-
hrs period of ischemia (Chaplin et al, 1994). 
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Finally, unlike angiogenesis inhibitors, VTAs should require only 
intermittent administration to synergize with conventional treatments rather 
than chronic administration over months or years. 
 
VTA approach Compound Comments 
Ligand-directed Antibody-TF 
Anti-VCAM1-TF 
L19 scFv-TF 
TF induces coagulation 
VCAM-1 is a cell adhesion marker 
L19 scFv targets fibronectin ED-B 
domain 
 VEGF-gelonin 
Anti-endoglin linked to ricin A 
Anti-TES-23 linked to 
Neocarzinostatin 
L19 scFv-IL-12 
L19 scFv-TNF-a 
Anti-PS 
Targeted ATPµ-Raf gene 
DNA encoding Flk-1 fused 
to Fas 
Gelonin is a plant toxin 
Antibody-toxin 
Antibody-cytotoxic 
 
Antibody-cytokine 
Antibody-cytokine 
Naked antibody 
Gene therapy, blocks signaling 
Gene therapy, induces apoptosis 
 
Small molecules CA4P 
ZD6126 
AVE8062A 
Oxi4503 
DMXAA 
 
Phosphate prodrug of CA4P 
Phosphate prodrug of N-
acetylcolchinol 
Combrestastatin analogue 
Combrestastatin analogue 
Flavonoid 
 
Table 2. Philip Thorpe et al, The first International Conference on Vascular Targeting: 
Meeting Overview. 
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THE αVβ3 and αVβ5 integrins as natural endothelial markers 
 
In the past decade, many molecules have been described to be up-regulated 
on angiogenic endothelial cells, which can in theory be therapeutically 
exploited (Schraa et al, 2002). 
Some of these molecules are the integrins αVβ3 and αVβ5, which recognizes 
RGD (Arg-Gly-Asp) motifs in extracellular matrix components (Brooks et 
al, 1994a), and are essentially absent from the normal tissues of an adult 
animal and are also selectively up-regulated in angiogenesis related 
diseases. 
Several members of the integrin family of adhesion receptors are expressed 
on the surface of cultured smooth muscle and endothelial cells. Among 
these integrins is αVβ3, the endothelial cell receptor for vitronectin, von 
Willebrand factor, fibrinogen and fibronectin (Cheresh, 1987). 
  
Cheresh showed that in both human and chick, blood vessels involved in 
angiogenesis have enhanced expressions of αVβ3, playing a key role in 
angiogenesis and suggesting that integrin αVβ3 will be a therapeutic target 
for diseases characterized by neovascularization (Brooks et al, 1994a).  
The αVβ3, αVβ5, α5β1 and other integrins are each up-regulated in 
angiogenic vessels and play a role in angiogenesis (Eliceiri et al, 1999). 
 
In the fetus, α5β1 is necessary for the development of the vasculature (Yang 
et al, 1993), whereas fetal or adult angiogenesis can occur without the αV 
integrins.  
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However, αVβ3 and αVβ5 are somehow important in adult angiogenesis 
because peptides and antibodies that perturb their function block 
angiogenesis (Ruoslahti, 2002).  
 
Recombinant fusion proteins 
 
General advantages of recombinant fusion proteins are: 
1 Easy production of defined homogeneous proteins 
2 Protein engineering can be performed on the DNA level 
3 The constructs can be produced as entirely human proteins, which 
addresses the previously described problem of immunegenicity 
(Kuus-Reichel et al, 1994). 
4 Easy experimentation on mice. 
 
The anti-tumor efficacy of tTF targeted to tumor vessels has already been 
proved; Huang et al, 1997, targeted the TF molecule to a class II antigen in 
a mouse neuroblastoma model through a bispecific antibody, transfecting 
first the mice with the IFN-y gene, to generate the expression of MHC class 
II antigens on the tumor vascular endothelium in mice. 
To target tTF to tumor vascular endothelium, a mixture of tTF and the 
bispecific F(ab´)2 antibody was injected in tumor allografted mice. The 
binding of tTF to MHC class II antigen on endothelial cells induced 
selective coagulation activation with tumor infarction. 
The treatment induced thrombosis of tumor vessels with 38% of complete 
regression. (Huang et al, 1997). 
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One year later Sophia Ran et al, from the same group used a coaguligand 
consisting of a monoclonal antibody to murine VCAM-1 (vascular cell 
adhesion molecule-1) covalently linked to tTF. By antibody directed 
targeting of tTF to the tumor vasculature selective infarction of solid 
Hodgkin's tumors in mice was mediated. 
The treatment induced thrombosis of tumor vessels and retarded tumor 
growth, complete tumor regression was not observed. A 50% reduction in 
tumor growth occurred, although VCAM-1 was present only in a minority 
of vessels (larger vessels within the tumor mass) (Ran et al, 1998). 
 
Dario Neri et al, used a similar approach by fusing an antibody fragment 
(scFv) specific for the oncofetal ED-B domain of fibronectin to tTF. The 
fusion protein mediated the complete and selective infarction of three 
different types of solid tumors in mice. 
In this approach 30% of mice exhibited a complete tumor regression in a 
single dose treatment, but showing also signs of toxicity and the animals 
were not cured (Nilsson et al, 2001).  
 
Liu C et al, coupled tTF to an inhibitor of prostate-specific membrane 
antigen. This protein induced selective local in vivo infarctive necrosis of 
the rat Mat Lu prostate tumor when administered intravenously (i.v.).  
The combined administration of this fusion protein with low-dose 
doxorubicin produced a profound tumoricidal effect, resulting in complete 
eradication of some tumors (Liu et al, 2002). 
  
Another group induced extravascular coagulation targeting a highly 
selective tumor stroma associated marker, they constructed a fusion protein 
comprising of a single-chain molecule of a fibroblast activation protein 
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(FAP)-specific humanized antibody [single chain fragment 
variable(scFv)OS4] and the extra cellular domain of human tissue factor. 
The fused protein scFv-tTF targeted to FAP induced an extravascular 
coagulation of the tumor stroma in an antigen-specific manner (Rippmann 
et al, 2000).  
 
Recently P. Hu et al 2003, generated three MAb fusion proteins that 
selectively block the blood flow to tumors by targeting different antigens; 
the first one the RGD/tTF, targets endothelial αVβ3 and αVβ5 integrins 
exposed on tumor vessels, the second fusion protein, chTV-1/tTF, targets a 
vessel antigen, fibronectin, which is located in the basement membrane of 
vessels and the third fusion protein, chTNT-3/tTF, targets necrotic regions 
of the tumor in which conserved and abundant intracellular antigens are 
exposed in degenerating cells. 
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OBJECTIVES 
 
The present study focuses on the fact that the human coagulation inducing 
protein tissue factor, is the major initiator of blood coagulation. The aim of 
this work was to investigate the feasibility of treating human solid tumors 
by selective delivery of human truncated tissue factor fused to RGD 
peptide sequences to the tumor vascular endothelium in a mouse model, as 
a new approach for cancer therapy.  
 
The objectives are: 
 
To demonstrate that the tTF-RGD fusion proteins selectively induce 
coagulation in the tumor vasculature in an animal model. 
 
To demonstrate the anti-tumor activity of tTF-RGD fusion proteins in a 
mouse xenotransplantation model. 
 
To demonstrate that the selective thrombosis of treated solid tumors in our 
approach should lead to regression and inhibition of tumor growth. 
 
To demonstrate the safety of this anti-vascular treatment strategy.  
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Material and methods 
 
Cell lines and antibodies: 
 
Lung cancer cell line (CCL185) were described earlier (Topp et al, 1993) 
and the melanoma tumor cell line (M21) as described was kindly provided 
by Dr. Silletti, University of California San Diego (USA)(Felding-
Habermann et al, 1992). Anti-tTF was obtained by Diagnostic international 
(Karlsdorf, Germany), Integrin αVβ3 and GRGDSP-peptide was obtained 
by Chemicon (Temecula, California, USA). Anti-Histag antibody (Santa 
Cruz Biotechnology). 
 
Construction of the E. coli expression vector for soluble TF (truncated 
TF [tTF1-219]) 
 
The c-DNA coding for tTF1-219 and tTF1-219-GRGDSP (short tTF-RGD) was 
amplified by polymerase chain reaction (PCR) using the primers : 
5‘CATGCCATGGGATCAGGCACTACAAATACTGTGGCAGCATATA
AT.3‘(5‘Primer)5‘CGGGATCCTATTATCTGAATTCCCCTTTCTCCTG
GCCCAT3‘(3`Primer) for tTF and 5‘CATGCCATGGGATCAGGCACTA 
CAAATACTGTGGCAGCATATAAT3‘(5‘Primer)5’CGGGATCCTATT 
ATGCATGTGCTCTTCCGTTACCTCTGAATTCCCC-3’(3‘-Primer) for  
tTF-RGD (primers from Oligofactory PE Applied Biosystems Germany). 
 
The RGD sequence was ligated to the carboxyl terminus of the tTF. This 
would allow the tTF-RGD to adopt an orientation perpendicular to the 
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phospholipid membrane of the cell similar to native tissue factor (Banner et 
al, 1996). 
On the other hand, ligation of the peptide to the carboxyl terminus of tTF 
should not result in a sterical hindrance for the interaction of tTF and its 
substrate FX.  
 
Expression, refolding and purification of tTF1-219 and tTF1-219 RGD 
peptide. 
 
With the DNA-Ligation Kit (Novagen, Madison, Wisconsin, USA), the 
cDNA were cloned into the expression vector pET-30(+)a (Novagen), 
using the Bam H 1 and NCO I restriction sites of the vector.  
The vectors were introduced into competent Escherichia coli cells (BL21 
DE3) according to the manufacturers protocol (Novagen).  
After stimulating with IPTG (Novagen) the cells were harvested and 5-7 ml 
lysis buffer (10 mM Tris-HCl, pH 7,5; 150 mM NaCl; 1 mM MgCl2; 10 
µg/ml Aprotinin; 2 mg/ml Lysozym) per gram wet weight and 20 µl 
Benzonase (Novagen) were added to the pellet.  
Then the cells were incubated for 90 minutes at RT and centrifuged at 
12,000 g for 20 min at 4°C. The pellet was resuspended and homogenized 
by sonicating in washing buffer (10 mM Tris/Hcl, pH 7,5; 1 mM EDTA; 
3% Triton X-100).  
 
To solubilize the inclusion bodies, 2-4 ml Guanidinium buffer (6 M GuCl; 
0,5 M NaCl; 20 mM NaH2PO4; 1 mM DTT) per gram wet weight was 
added. After incubation over night at RT, the suspension was centrifuged at 
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5,000g for 30 min at 4°C. The supernatant was filtered through a 0,22 µm 
filter. 
  
Purification and refolding was done with the His Bind Buffer Kit 
(Novagen) according to the manufacturers protocol. To remove the salt, the 
suspension was dialyzed in a Slide-A-LyzerR 10 K dialysis cassette 
(Pierce, Rockford, Illinois, USA) against TBS buffer. 
 
Characterization of tTF1-219 and tTF1-219 RGD peptide 
 
For chemical characterization, sequences of the coding cDNA in the 
expression plasmids are confirmed in an automatic sequencer equipped 
with laser and CCD-camera (ABI PRISM 310, Perkin Elmer). N-terminal 
amino acid sequences of proteins are confirmed by Edman degradation and 
amino acid analyses is performed additionally ( Applied Biosystems 
Sequencer Model 477A and AS-Analyzer 120A). Subsequently, 
SDS/PAGE and Western Blot analyses are carried out with antibodies 
against tTF  
 
SDS-PAGE and Western blot analysis 
 
The purified tTF-RGD fusion proteins were analysed by SDS-PAGE as 
described above.The presence of the tTF moiety for each fusion protein 
was further confirmed by western blotting analyses. 
The protein samples were diluted trying to obtain a similar concentration 
between them. Using a precision protein standard (Bio-rad) the 
electrophoresis was runned at 120 volts and later stained with Gel code 
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blue stain reagent (PIERCE). The tTF-RGD fusion proteins in the SDS-
PAGE gel (ready gel Bio-rad, 4°C) were transferred to a PVDF membrane 
overnight at 30 volts and 90 mA. 
To identify those bands containing the tTF and tTF-RGD fusion proteins, 
the protein immunoblotting (Opti-4CN amplified, Bio-Rad) was done 
incubating the fusion proteins with a primary antibody (anti-Histag Santa 
Cruz biotechnology) biotin conjugated and a HRP antibody (streptavidin 
HRP). 
 
Tumor endothelial cells 
 
Figure 1. Schematic 
representation of the binding of 
the fusion protein tTF-RGD, to 
avß3-integrin. 
This receptor is selectively 
expressed in high density on tumor 
endothelial cells, but with few 
exceptions not in quiescent 
endothelial cells in normal tissues. 
 
 
Binding of tTF1-219 and tTF1-219 RGD peptide to FVIIa 
 
The apparent dissociation constant (Kd) for the interaction of the tTF 
constructs with FVIIa are calculated employing a published method based 
on the amidolytic activity of the tTF:VIIa complex towards the 
chromogenic substrate Spectrozyme Factor Xa (American Diagnostica) 
(Ruf et al, 1991a and b). 
Into each well of a microtiter plate the following reagents are added: a) 26 
µl 0.05 M Tris/HCl, 0.15 M NaCl, pH 7.4, 0,1 % bovine serum albumin 
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(TBS-BSA). b) 26 µl tTF 1-219 and the tTF 1-219-RGD peptide, respectively, 
diluted in TBS-BSA in concentrations ranging from 300 pM to 25 µM and 
c) 26 µl 8 nM recombinant FVIIa (Novo-Nordisk) in TBS-BSA. After 15 
min at RT, 26 µl of Spektrozyme Factor Xa are added and the initial 
reaction is monitored by change in absorption at 405 nm on a microplate 
reader (Bio-Rad, Hercules, California, USA). 
Rates are converted into concentrations of tTF:VIIa. On the basis of 
calculated free and bound ligand, the apparent Kd is determined by fitting 
these data to the single-site-binding equation: 
 
(number of bindings sites x [free ligand]) 
[Bound ligand] =         ________________________________________ 
 
([free ligand] + Kd) 
 
Factor X activation by tTF and tTF-RGD 
 
The ability of tTF and tTF-RGD to enhance the specific proteolytic 
activation of Factor X by Factor VIIa was assessed as described by Ruf et 
al (104). Briefly, to each well in a microtiter plate was added 20 µl of: (a) 
50 nM recombinant FVIIa (Novo-Nordisc) in TBS-BSA; (b) 0,16 nM –1,6 
µM tTF/tTF-RGD in TBS-BSA; (c) 25 nM CaCl2 and 500 µM 
phospholipids (phosphatidylcholine/ phosphatidylserine, 70/30, MM; 
Sigma). 
After 10 min at room temperature, 20 µl of the substrate Factor X (Enzyme 
Research Laboratories) was added in a concentration of 5 µM. 
Aliquots were removed from the reaction mixture every minute and 
stopped in 100 nM EDTA. Spectrozyme FXa was added and rates of Factor 
Xa were monitored by the development of color at 405 nm. 
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The activity of tTF-RGD bound to microvascular endothelial cells (MVEC) 
was determined in vitro by using a chromogenic assay to detect FXa as 
described by Ran et al, 1998.  
Briefly, MVEC were grown in a 96 well plate to confluence. The cells were 
washed two times with PBS-buffer containing 2mg/ml BSA. The cells were 
incubated with different concentrations of tTF-RGD (0,025-0,4 nM) for 20 
min at 37°C.  
To each well in the microtiter plate was added: (a) 50 µl of Tris/HCl, 0,15 
M NaCl, pH 7,4, 0,1% BSA (TBS-BSA); (b) 25 µl of 10 nM recombinant 
FVIIa (Novo Nordisk, Bagsværd, Denmark) in TBS-BSA; (c) 25 µl of 5 
mM CaCl2 in TBS-BSA.  
 
After an incubation time of 20 min at room temperature, 100 µl of each 
well was transferred to a new 96-well plate. 50 µl of 1,1 M EDTA and 25 
µl of Spectrozyme FXa (5nM) were added.  
 
The breakdown of substrate was measured by reading the absorbance in a 
microplate reader (Bio-Rad, Hercules, California, USA) at 405 nM. The 
cells were detached and counted. The results are expressed as the amount 
of FXa generated per 104 cells. 
 
Binding of tTF-RGD fusion proteins to its targets 
 
The binding of tTF-RGD to purified immobilized αvβ3 (Chemicon) was 
analyzed by ELISA (enzyme linked immunoadsorbent assay) techniques as 
described earlier (Silleti et al, 2001). Binding steps were performed in the 
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absence and presence of the synthetic peptide GRGDSP (Chemicon) as 
competitive ligand in order to show the specificity of this interaction.  
Subsequently, the specific binding of tTF-RGD to αvβ3 on endothelial cells 
was evaluated.  
 
To this end, the differential binding of biotinilated tTF and tTF-RGD on 
endothelial cells in suspension was analyzed by FACS. Streptavidin-
phycoerythrin has been employed for detection of bound protein (See 
fig.4). 
 
Tumor Xenotransplantation models 
 
All procedures on animals were performed in agreement with german 
regulations (Tierversuchsgesetz § 8 Abs. 2) and specifically approved in 
form of a project license. 
 
Single cell suspension (2 x 106 in 100µl) of CCL185 (human 
adenocarcinoma of the lung) or M21 (human melanoma) were injected 
subcutaneously (s.c.) into the right anterior flank of male BALB/c nude 
mice (9-12 weeks old).  
 
Tumor growth was allowed to a volume of approximately 50-100 mm3 
(CCL185) and 500-700 mm3 (M21), respectively. At this point, mice were 
randomly assigned to different experimental groups. Group 1 received 
0.9% NaCl (100 µl), group 2 tTF (30µg in 100µl 0.9% NaCl) and group 3 
tTF-RGD (30µg in 100µl 0.9% NaCl) via tail vein injection.  
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Depending on the growth kinetics injections were repeated twice weekly 
for five times (CCL185) or daily for five times (M21). 
 
Tumor size in vivo was evaluated using a standard caliper measuring tumor 
length and width in a blind fashion. Tumor volumes were calculated using 
the standardized formula (length x width² x π/6). 
 
According to our project license, animals had to be euthanazed when 
tumors became too large, if mice lost >20% of body weight, or at signs of 
pain. 
 
Representative photographs of animals and tumors were taken at the end of 
each experiment (data not shown). Next, mice were sacrificed by cervical 
dislocation in deep CO2 anesthesia in agreement with standard regulations 
and project license. 
 
Immediate debleeding was achieved by injection of NaCl 0,9 % and 
heparinized solutions directly into the left cardiac ventricle and opening 
femoral vessels. Tumors and organs (heart, lung, liver, kidney) were 
excised and fixed in 4% buffered formaldehyde solution before embedding 
in paraffin. 
 
For toxicity studies an extra set of animals was injected with a higher dose 
of tTF-RGD (50µg) and analyzed for signs of thrombosis in heart, lung, 
kidney or liver 1h, 4h or 24 hrs after injection in a similar manner.  
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Histological studies 
 
Histological analyses, was performed as described earlier (31). Briefly, to 
assess the toxicity of treatment by histological analysis, organs (heart, lung, 
liver and kidney) were collected 1h, 4 hrs and 24 hrs after injection of 2.0 
mg/kg/body weight of tTF-RGD, tTF and saline, fixed in 4 % buffered 
paraformaldehyde and embedded in paraffin.  
Four µm sections were cut and transferred onto glass slides. 
At least, 10 sections per sample were available for evaluation. 
Hematoxylin-Eosin (H&E) stained sections from organs were analyzed 
using conventional light microscopy for signs of necrosis and thrombosis in 
a blinded fashion. 
 
Mice were sacrificed at different time points after injection of 
2.0mg/kg/body weight. The tumors were excised, fixed in 4 % buffered 
paraformaldehyde and embedded in paraffin. Sections were cut and stained 
with H&E.  
 
Thrombosis of vessels was defined as complete or incomplete occlusion of 
intratumoral vessels by closely packed red blood cells. 
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STATISTICS 
 
The data are presented as medians and interquartile ranges. 
The binding differences between tTF and tTF-RGD and the differences in 
tumor growth rates between treated tTF-RGD mice and control mice (tTF 
or NaCl) were tested for statistical significance using a nonparametric test 
(Mann-Whitney rank sum test) for independent samples that makes no 
assumptions about tumor size being normally distributed. 
P values of <0.05 were considered significant. 
In the tumor growth analyses the data are presented as means, standard 
deviation (SD) and standard error. 
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RESULTS  
Characterization of tTF and tTF-RGD 
After expression and purification, tTF and tTF-RGD were analyzed under 
denaturing conditions on SDS-PAGE and Western-blot (See fig. 1-2 and 
3). 
 
 
 
 
 
 
    M            1         2            3 
Figure.2. SDS-PAGE ( Electrophoresis ready gel-Bio rad) M=molecular weight marker, 
1=tTF, 2=tTF-RGD, 3=tTF-RGD  
 
 
 
 
 
 
Fig. 3 Western-blot analyses of recombinant tTF and tTF fusion proteins. The 
purity and identity of tTF and tTF fusion proteins was verified using SDS-PAGE (Gel 
code blue ) and Western-blotting (monoclonal anti-tissue factor antibody clone VIC7 
American Diagnostics, anti-Histag ab. Santa Cruz) following extraction from E. coli 
(BL21 DE3) and refolding with a linear urea-gradient (6M – 1M). M=molecular weight 
marker, 1-4 = tTF, 5=tTF-RGD, 6=tTF-NGR. 
37 kd
25kd
37 kd 
25 kd 
 
 
 
Western-blotting, of tissue factor fusion proteins. 
     M                      1            2         3                     4          5         6 
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Factor X activation by tTF and tTF-RGD 
 
The ability of tTF and the tTF fusion proteins to enhance the specific 
proteolytic activation of factor X (FX) by Factor VIIa (FVIIa) is 
demonstrated by Michaelis-Menten analyses. The calculated Michealis 
constants (Km) for tTF and the tTF-RGD was within the range of 0.15 nM 
as reported in the literature (104a) (Figure 4). Thus, the ligation of the RGD 
peptide sequence at the carboxyl terminus of tTF does not affect its 
functional activity. 
 
 
Figure 4. Determination of the Michaelis constant (Km):  
For the activation of FX by FVIIa / tTF and FVIIa / tTF fusion proteins the Michaelis-
Menten kinetics were calculated according to a published method (104). 
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Binding experiments of tTF fusion proteins (tTF-RGD) to purified αvβ3 
 
The specific binding of tTF-RGD to immobilized αvβ3 is shown in a 
purified receptor binding assay (Figure 5.a-b). Binding of our construct to 
immobilized αvβ3 was dose-dependent and saturable. The specificity of this 
RGD-dependent interaction is underlined by the competition of the 
synthetic peptide GRGDSP. In the presence of 10-100 fold molar excess of 
synthetic RGD peptide our construct showed merely no significant binding 
capability to αvβ3.  
 
 
 
 
 
 
 
 
 
Figure 5 a 
Binding of tTF, tTF-RGD to the integrin 
αvβ3. The binding of 0.1µM tTF, tTF-
RGD to immobilized αvβ3  was detected 
with a polyclonal antibody against human 
TF by ELISA. The results are presented as 
median and interquartile range. The 
difference in binding between tTF-RGD 
and tTF was significant (p<0.005, Mann-
Whitney-Test). 
 Figure 5b 
Specificity of the binding of tTF-RGD to 
integrin αvβ3 . The binding of tTF-RGD 
(0.1µM) to immobilized avß3 was 
significantly inhibited by the synthetic 
peptide GRGDSP (p<0.005, Mann-
Whitney test for both RGD peptide 
concentrations). 
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Binding of tTF-RGD on endothelial cells  
 
Subsequently, the specific binding of tTF-RGD to receptors on endothelial 
cells (MVEC) was evaluated by FACS. Differential binding of biotinilated 
tTF and tTF-RGD on endothelial cells in suspension is shown.(Figure 6A). 
Indeed, the measured fluorescence intensity was eight fold higher for tTF-
RGD compared to tTF. Furthermore, the binding of 0,1 µM tTF-RGD to 
endothelial cells was reduced to 25% in the presence of 1 µM synthetic 
peptide GRGDSP. These results underscore again the RGD-dependency of 
tTF-RGD binding to receptors on endothelial cells such as integrins αvβ3 or 
αvβ5 (See fig. 6B). 
A 
Cell 
count  
Fluorescence intensity 
B 
 
 
Fluorescence intensity 
Figure 6. Binding of tTF and tTF-RGD to human endothelial cells. A) FACS 
analyses of endothelial cells that were incubated with 0.1 µM (2) or with 0.1 µM tTF-
RGD (3)for 60 min. at 4°C. B) By the addition of 1 µM GRGDSP the binding of the 
tTF-RGD fusion protein to endothelial cells was reduced by 75% due to competitive 
inhibition (4). Line 1 in A and B shows the negative control. 
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Anti-tumor activity of tTF-RGD in human malignant melanoma 
tumors 
 
The anti-tumor activity of the tTF-RGD fusion protein was determined in 
BALB/c nude mice bearing 500-700 mm3 M21 tumors (human malignant 
melanoma). The saline solution, tTF (20µg) and tTF-RGD (20µg) in 200 µl 
saline solution respectively, were administered i.v. five times at intervals of 
24 hours. The pooled results of two independent experiments are presented 
(Figure 7). 
 
The tumor growth was significantly retarded at the 4th day of the treatment 
(P=0,001) in comparison to tTF and saline treatment.  
The tumor weight was in the tTF-RGD treated group significant lower in 
comparison to the control groups (P=0,001). 
  
During treatment tumors showed macroscopic signs of necrosis within 24 
hours of treatment start similar to the results published by other groups 
(Huang et al, 1997; Ran et al, 1998; Nilsson et al, 2001; Liu et al, 2002; 
Peisheng et al, 2003). Besides, histological studies revealed substantial 
amount of tumor vessels which were thrombosed and confirmed the 
macroscopic impression of gross tumor necrosis. Thus, the presumable 
mode of action of the tTF-RGD fusion protein, i.e. the thrombotic 
occlusion of tumor vessels is underlined by these observations. 
The high selectivity of the tTF-RGD for tumor blood vessels is 
demonstrated by the fact that no visible thrombosis or necrosis occurred in 
normal tissues such as heart, kidney, liver, and lung (see fig 8). Even 
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repeated high doses of tTF-RGD (4 mg/kg body weight) did not cause any 
thrombosis or visible organ damage. 
 
 
 
Figure 7. Anti-tumor activity of tTF-RGD on growth of M21 tumors in mice 
The anti-tumor activity of the tTF-RGD fusion proteins was determined in BALB/c 
nude mice bearing M21 tumors. The tTF, saline solution and tTF-RGD respectively, 
were administered i.v. five times at intervals of 24 hours. The tumor growth was 
significantly retarded at the 4th day of the treatment (P=0,001) in comparison to tTF and 
saline treatment. The tumor weight in the tTF-RGD treated group was significantly 
lower in comparison to the control group (P=0,001).  
 
Anti-tumor activity of tTF-RGD in human lung cancer tumors in mice 
 
Furthermore, we determined the anti-tumor activity of the tTF-RGD 
protein in BALB/c/nude mice bearing 50-100 mm3 CCL185 (human lung 
cancer) tumors. Because of the slower tumor growth in the experiment, the 
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tTF-RGD (20µg) and the controls tTF(20µg) and saline solution were 
administered five times at intervals of 3-4 days.  
The pooled results of two independent experiments are represented (Fig.8). 
After the 5th injection of tTF-RGD, we could show a significant growth 
inhibition of the CCL185 tumors in comparison to the control groups 
(P=0,001).  
 
 
Figure 8. Anti-tumor activity of tTF-RGD on growth of CCL-185 tumors in mice  
The anti-tumor activity of the tTF-RGD fusion proteins was determined in BALB/c 
nude mice bearing CCL185 tumors. Because of the slower tumor growth in the 
experiment, the tTF-RGD, the tTF and the saline solution, respectively, were 
administered at intervals of 3-4 days. After the 5th injection of the tTF-RGD, we could 
show a significant growth inhibition of the CCL185 tumors in comparison to the control 
groups (P=0,001).  
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Histological analyses from mice organs treated with tTF-RGD  
 
All animals were macroscopically and histologically analyzed after 
treatment. The organs (heart, kidney, liver and lung) from the tTF-RGD 
treated mice didn’t show any sign of thrombosis or necrosis (See figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Representative H&E sections of heart (A), kidney (B), liver (C) and lung (D),  
1 hour after injection of 4 mg/kg/body weight of tTF-RGD in the mice. No visible 
thrombosis or necrosis was observed in these organs (magnification x 200). 
 
The high selectivity of tTF-RGD for tumor blood vessels is demonstrated 
by the fact that no visible thrombosis or necrosis occurred in normal tissues 
such as heart, kidney, liver and lung (Fig. 10).  
A B 
C D
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Histological analyses of the effect of tTF-RGD on tumor tissue 
 
The microscopic studies revealed that tumor vessels of the malignant 
melanoma and lung cancer were thrombosed (Fig. 10 A-B). Thus, the 
presumable mode of action of tTF-RGD, i.e. the thrombotic occlusion of 
tumor vessels is confirmed by these observations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Representative Hematoxylin/eosin (H&E) sections of the malignant 
melanoma (M-21) tumor bearing mouse, 1 hour after injection of tTF-RGD (A 
and B) or saline control (C and D) in the tail vein of the mice. Blood vessels in 
tumors treated with tTF-RGD fusion proteins appear thrombosed (arrows). In  
the area surrounding an occluded blood vessel extensive tumor cell necrosis is 
observed (A-B). Photographs are from representative areas of the tumor (A and 
C: magnification x 200; B and D magnification x 400). 
 
A 
DC 
B
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Macroscopic experiment showing the effect of the tTF-RGD on tumor 
treated mice 
 
In order to prove the mode of action that thrombotic occlusion of tumor 
vessels does really occur, the following experiment was performed: 
The human melanoma cell line M-21 was injected into the flank of two 
male balb/c/nude mice. After having reached a tumor volume of 
approximately 500 mm3,  2.0 mg/kg/body weight of tTF-RGD or 0,9 % 
NaCl was injected in the tail vein of the mice.  
 
See the photograph of the tumor bearing mouse 20 minutes after injection 
of the tTF-RGD fusion protein (left side) and 0.9 % NaCl (right side) 
respectively (Figure 11 A). 
 
The tumor was bruised and blackened indicating apparent massive tumor 
ischemia after injection of tTF-RGD.  
The mice were sacrificed 60 min. after injection and the tumor was 
completely removed for histological studies (data not shown). 
 
We could see areas of hemorrhage and ischemia in the tumor of the mouse 
treated with tTF-RGD in contrast to the apparent vital appearance of the 
tumor treated with saline solution after injection. 
(Figure 11 B-C). 
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Figure 11. A, Representative photographs of the malignant melanoma (M-21) 
tumors bearing mice 20 minutes after injection of the tTF-RGD fusion protein (left 
side) and 0.9 % NaCl (right side), respectively. The tumor was bruised and blackened 
indicating massive tumor ischemia after injection of tTF-RGD. B, shows areas of 
hemorrhage in the tumor of the mouse treated with tTF-RGD in contrast to the vital 
appearance of the tumor treated with 0.9 % NaCl solution C. 
 
 
 
 
 
 
 
 
 
A 
CB 
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DISCUSSION 
 
The initial reports on the selective induction of intratumoral thrombosis 
using tTF fused to antibodies or antibody fragments directed to artificial or 
natural markers of angiogenesis showed impressive efficacy in terms of 
tumor growth inhibition. The first report by Huang et al, on the targeted 
induction of intraluminal blood coagulation in tumor blood vessels using an 
artificial marker of angiogenesis generated a great interest to learn whether 
the same strategy would work in tumor models carrying natural markers of 
angiogenesis.  
The second report on this strategy, featuring the targeting of the VCAM-1, 
was less impressive because only a 50% reduction in the tumor growth rate 
was observed. 
The third report by Nilsson et al, featuring the targeting of the mice ED-B 
domain sequence in the vasculature of aggressive growing tumors observed 
a complete remission in 30 % of the mice treated, however animals were 
not cured (Huang et al, 1997; Ran et al, 1998; Nilsson et al, 2001). 
 
One last report by Peisheng Hu et al 2003, shows the results of three 
different targeted tissue factor fusion proteins for inducing tumor vessel 
thrombosis; the chTNT-3/tTF which targets the antigens exposed in 
necrotic regions of the tumor, the chTV-1/tTF targets a vessel antigen, 
fibronectin and RGD/tTF similar to the fusion protein constructed in our 
approach. 
 
Of interest, a comparison of the three targeting approaches from Hu et al, to 
deliver the tTF to the tumor site demonstrated that chTNT-3 and chTV-1 
were found to be the most effective vehicles. Interestingly, RGD/tTF alone 
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did not display significant anti tumor effects on its own. The authors 
explained this by the fact that the receptor for RGD, αVβ3 , is mainly 
associated with endothelial cells undergoing angiogenesis known to occur 
principally in newly formed capillaries and small sized vessels, not larger 
sized, mature vessels. Moreover, they argued that the RGD receptors have 
a relative low affinity for a ligand compared with antigen-antibody 
interactions, thus explaining the less impressive results obtained with this 
fusion protein (Peisheng Hu et al, 2003).  
 
Antibody fusion proteins highly depend on the appropriate formulation to 
prevent protein aggregates associated side effects. The bigger size of even 
single-chain antibody fragments which are fused to tTF may be of sterical 
hindrance to tTF in terms of inducing coagulation. Promising candidates to 
target tTF to the tumor vasculature without the above mentioned drawbacks 
include small peptide fusion proteins selective for natural markers on tumor 
endothelium (Baxter et al, 1989). 
Integrins αVβ3, αVβ5 as well as other integrins have been identified as 
markers of activated endothelium and seem to play a crucial role in 
developmental and tumor angiogenesis (Fujimori et al, 1989; Jain, 1990; 
Denekamp, 1990). 
RGD-peptide fusion proteins which bind to these endothelial ligands have 
been identified as promising agents to target the tumor endothelium (Arap 
et al, 1998). 
 
In this study, we show the ability of tTF and tTF-RGD fusion protein to 
enhance the specific proteolytic activation of factor X (FX) by Factor VIIa 
(FVIIa). The calculated Michaelis constants (Km) for tTF and the tTF-RGD 
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were within the range of 0.15 nM as reported in the literature, 
demonstrating the efficacy of our tTF to activate coagulation. 
The specific binding of tTF-RGD to immobilized αvβ3 is shown in a 
purified receptor binding assay. Binding of our construct to immobilized 
αvβ3 was dose-dependent and saturable. The specificity of this RGD-
dependent interaction is underlined by the competition using the synthetic 
peptide GRGDSP. In the presence of 10-100 fold molar excess of 
unlabeled synthetic RGD peptide, our construct showed merely no 
significant binding capability to αvβ3, thus suggesting the specificity of 
tTF-RGD binding to αvβ3. 
 
The anti-tumor activity of the tTF-RGD fusion protein was evaluated in 
BALB/c nude mice bearing 500-700 mm3 M21 tumors (malignant 
melanoma) and 50-100 mm3 CCL185 tumors (lung cancer). The tumor 
growth was significantly retarded in comparison to tTF alone and saline 
treatment. Moreover, the tumor weight was significant lower in the tTF-
RGD treated group in comparison to the control group.  
 
In the groups of control mice, there was no statistically significant 
difference between mice injected with saline or with tTF protein alone, no 
macroscopically signs of ischemia or occluded vessels by histological 
analyses, confirming that the selective targeting of tTF-RGD was necessary 
for the anti-tumor effect. 
 
In our approach, the injection of the tTF-RGD fusion protein in mice 
through the tail vein shows the efficacy of the fusion protein without 
significant side effects in vivo. 
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Our effective tumor growth inhibition may be explained by the fact that the 
receptors for RGD, αVβ3, αVβ5 are associated with endothelial cells 
undergoing angiogenesis.  
Moreover, by the suggestion that for optimal effects tTF needs to be 
targeted to the luminal surface of the tumor endothelium in all regions of 
the tumor mass, probably because platelet activation, assembly of 
coagulation factors, or both occur most efficiently on the luminal side 
(Brooks, PC et al, 1994b). 
The mechanism of vessel thrombosis with the reagent is readily understood 
because RGD receptors are located on the luminal side of tumor vessels 
(Ran et al, 1998; Nilsson et al, 2001). 
 
According to that and based on the known crystal structure of the 
tTF:FVIIa complex (Banner et al, 1996), the fusion to RGD would allow 
the tTF-peptide fusion proteins to adopt an orientation perpendicular to the 
phospholipid membrane of the endothelial cell similar to native TF.  
On the other hand, ligation of the peptide to the carboxyl terminus of tTF, 
as done in our work, should not result in a sterical hindrance for the 
interaction of tTF with FVIIa and its substrate FX. 
 
This work shows for the first time an effective in vivo inhibition of human 
tumor growth by selectively targeting the tTF-RGD fusion protein to 
natural markers of angiogenesis. The selective induction of intraluminal 
blood coagulation in the tumor vasculature, results in effective anti tumor 
therapy in two experimental solid tumor mice models. However, future 
preclinical studies are necessary to optimize this antivascular treatment 
strategy, e.g. by combining tTF-RGD with cytotoxic agents or other 
antiangiogenic drugs. 
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ABBREVIATIONS 
 
TF = Tissue Factor 
tTF= truncated form of tissue factor 
RGD = specific peptide sequence 
PS = phosphatidylserene 
VEGF = vascular endothelial growth factor 
VCAM-1 = vascular cell adhesion molecule 
B-FN = fibronecting containing ED-B 
FACS = fluorescence activated cell sorting 
MVEC = microvascular endothelial cells 
Kd = dissociation constant 
ELISA = enzyme linked immunoadsorbent assay 
Ang1 = angiopoietin-1 
ED-B= domain extra domai-B of fibronectin 
FVIIa= activated factor VII 
TNF-α= Tumor necrosis factor alpha 
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